

REMARKS

In response to the Office Action mailed January 9, 2006, Applicants amended claims 1-5 and 35-38, and the specification. A substitute specification (a clean version and a version with markings to show the changes) is attached. The amendments to the specification insert sequence identifiers and correct typographical errors. The amendments in the substitute specification include amendments made by the Preliminary Amendment filed with the application on November 19, 2003; amendments filed November 2, 2005; and further amendments to address the Examiner's concerns in the Office Action dated January 9, 2006. No new matter has been added by the amendments. Claims 1-7 and 34-48 are presented for examination.

Objections to the Specification

A substitute specification is attached. Amendments to the specification include the insertion of sequence identifiers. The specification is believed to comply with the requirements of 37 C.F.R. § 1.821 through § 1.825.

The specification was also amended to clarify the experimental details in Example 1 (at page 19 of the original application). An amendment corrects a typographical error by changing "2M formate" to "0.2M formate."

The Examiner objected to the claims, because the three-letter amino acid codes were written with three capital letters. The claims have been amended such that the three-letter amino acid codes are written with a first capital letter followed by two lower case letters. To be consistent, this change was also made in the specification.

The amendments to the specification and the claims are believed to overcome the objections.

35 U.S.C. § 112, first paragraph

Written Description. The Examiner maintained the rejection of claims 1-7 and 34-48 under 35 U.S.C. § 112, first paragraph for lack of written description. The Examiner contends that the amino acid sequences of ACP and ACPS must be defined. *See* Office Action at page 3. Applicants do not concede that the Examiner's position is appropriate. However, to further

prosecution, claim 1 has been amended to insert the sequence identifiers SEQ NO:1 and SEQ ID NO:2 as suggested by the Examiner. In view of the foregoing, Applicants request reconsideration and withdrawal of the rejection of the claims under 35 U.S.C. § 112, first paragraph, for lack of written description.

Enablement. The Examiner maintained the rejection of claims 1-7 and 34-48 under 35 U.S.C. § 112, first paragraph for lack of enablement. The Examiner states that "Applicants have presented no evidence or, indeed, any arguments to establish the adequacy of the disclosure to enable the scope of the instant claims." *See* Office Action at page 3.


Applicants do not concede that the Examiner's position is appropriate. However, in view of the amendment to claim 1, specifying that the sequence of ACPS is as set forth in SEQ ID NO:2 and the sequence of ACP is as set forth in SEQ ID NO:2, the claims are certainly enabled, because, *inter alia*, Example 1 describes explicitly how to generate a crystallized complex as encompassed by the claims. Furthermore, the Examiner conceded at page 14 of the Office Action dated July 13, 2005, that the specification is enabling for polypeptides described by SEQ ID NOs:1 and 2. In view of the foregoing, Applicants request reconsideration and withdrawal of the rejection of the claims under 35 U.S.C. § 112, first paragraph, for lack of enablement.

Applicants believe the application is in condition for allowance, which action is requested.

No fees are believed to be due. However, any necessary charges, or any credits, should be applied to Deposit Account No. 06-1050, referencing Attorney Docket No. 16163-031002.

Respectfully submitted,

Date: March 3, 2006


Allyson R. Hatton, Ph.D.
Reg. No. 54,154

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110
Telephone: (617) 542-5070
Facsimile: (617) 542-8906